Introduction
Drug-dependent antibodies (ddAb)' occur in patients sensitized to certain medications, which are most commonly quinidine or quinine (1) . Patients develop profound thrombocytopenia when their platelets become coated with ddAb in the presence of the sensitizing drug. Drugs like quinidine and quinine bind weakly to platelets in the absence of ddAb (2, 3) ; excess soluble drug is required for maximum ddAb binding to platelets (3); and excess soluble drug fails to displace platelet-bound ddAb (2, 3) , but it is not yet certain whether ddAb interact with platelets via the Fab or the Fc portion of the antibody molecule. That ddAb binding to platelets might occur via the Fc portion was suggested by two recent studies (4, 5) , in which F(ab')2 fragments of ddAb did not bind demonstrably to platelets in the presence of drug. In the present study, we used intact ddAb and Staphylococcus aureus protein A-Sepharose 1. Abbreviations used in this paper: anti-Fc and anti-F(ab')2, F(ab')2 fragments of affinity-purified antibodies specific for the Fc and the F(ab')2 portions of human IgG, respectively; ddAb, drug-dependent antibody; EBP, EDTA-BSA-phosphate-buffered saline; PGE,, prostaglandin E,; SpA beads, protein A-Sepharose.
(SpA beads) to investigate the molecular orientation with which ddAb bind to platelets. Our findings suggest that this interaction occurs via the Fab portion of the IgG molecule.
Methods
Chemicals and reagents. Quinine hydrochloride, quinidine hydrochloride, normal human IgG, prostaglandin E, (PGEI), and bovine serum albumin (BSA) (fraction V) were purchased from Sigma Chemical Co. (St. Louis, MO). SpA beads (CL4B) were obtained from Pharmacia Fine Chemicals (Piscataway, NJ). Affinity purified goat anti-human IgG, F(ab')2 fragments, specific for either the Fc (anti-Fc) or the F(ab')2 (anti-F(ab')2) portion of the molecule, were from Pel-Freez Biologicals (Rogers, AK).
Patients. Plasma from four patients with confirmed drug-induced immunologic thrombocytopenia (1), two with quinineand two with quinidine-dependent antibodies (designated PB, GC, LG, and WW, respectively), and plasma containing an anti-PIAI antibody from a patient with posttransfusion purpura were used. Patients CG, LG, and WW were designated antibodies 1, 7, and 16, respectively, in a previous report (6) .
Rosettes with antibody-coated platelets and SpA. Platelet-rich plasma was isolated from whole blood (anticoagulated with 7.6 mM EDTA) by differential centrifugation as previously described (7) . Platelets (I X 0I in 200 !d plasma) were incubated with 500 Ml of normal plasma or patient plasma containing either ddAb or anti-PIll antibody (previously heated at 560C for 30 min and centrifuged at 12,800 g for 15 min at 4VC in an Eppendorf Micro centrifuge, Brinkmann Instruments, Inc., Westbury, NY). In the case of ddAb, 300 MM final concentration of the sensitizing drug or EDTA-BSA-phosphate-buffered saline (EBP) (8 mM EDTA, 1% BSA wt/vol, 0.1 M NaH2PO4, 0.15 M NaCl, pH 7.2) were also added. The mixture was incubated for 30 min at room temperature with gentle rotation. Some experiments were modified by the addition of 20 ng/ml PGEI and/or the use of lower drug concentrations (10-30 MuM). Cells were then washed twice in EBP that contained I mM sensitizing drug (ifthe initial mixture contained drug) and resuspended in 200 Md EBP containing 300 M&M drug (all samples).
Rosettes were formed by mixing 20 Mul EBP that contained 300 jM drug, 20 Ml antibody-coated platelets (I X 107), and 10 Ml SpA beads (packed volume diluted 1:10 in EBP) in a 96-well flat bottom plate (Costar, Cambridge, MA) pretreated with 5% BSA in EDTA-phosphatebuffered saline (PBS) for 30 min and rinsed once with EBP. Rosette formation occurred over 12 h at 40C and was evaluated microscopically by gently adding 5 Ml of each reaction mixture to 20 Ml EBP on a standard microscope slide with coverslip. Partial purification ofplatelet antibodies. Plasma (50 ml) containing ddAb was incubated with 300 MM sensitizing drug and 2 X 1010 platelets (previously washed three times in EDTA-PBS, pH 7.3) in a final volume of 55 ml for 30 min at room temperature. After three washes with I mM drug in EDTA-PBS, the antibodies were eluted from the platelets with chloroform (8) and dialyzed exhaustively against PBS. IgG concentrations were determined by electroimmunoassay (9) and ranged between 100 and 200 Mg/ml. The fraction of the IgG consisting of ddAb was determined by incubating samples of the eluate (containing I Ag of total IgG) in the presence and absence of I mM sensitizing drug with increasing numbers of washed platelets (5 X 106-5 X 107 platelets/II) for 20 min at room temperature. Mixtures were then centrifuged at 12,800 g for 2 min, and supernatants were analyzed for IgG content by electroimmunoassay (3) . The difference in IgG content of the eluate absorbed with platelets in the presence and absence of drug ranged between 20 and 40% of the total IgG and was assumed to represent drug-dependent platelet antibody. Eluates of the anti-PiA antibody were similarly prepared without the use of drug and their content of specific IgG determined by absorption with P1A`positive and PlA-negative platelets.
Rosettes with antibodycoated SpA beads and platelets. SpA beads (100 Al of a 1:10 dilution of packed beads) were incubated either with eluates containing 150 jig IgG, of which 19-27% was ddAb or anti-PI"A antibody, or with 150 ug of normal human IgG for 30 min at room temperature, washed twice with EBP, and resuspended in 100 ILI EBP. Rosettes were induced as described above by incubating 10 ji antibodyor normal IgG-coated SpA beads with I X 107 platelets, followed by two washes in EDTA-PBS and resuspension in 20 jI EBP.
In the case of ddAb, I mM sensitizing drug was present in the wash solutions.
Inhibition of rosette formation. Antibody-coated platelets were resuspended in 100Il EBP that contained I mM sensitizing drug, and 50 Al of this suspension (5 X 107 platelets) was incubated with 50 jl of the F(ab')2'fragments of anti-Fc or anti-F(ab')2 antibody at various dilutions (5-500 jg/ml final concentration) for 30 min at room temperature before addition of SpA beads. Rosette formation was induced and visualized as described above. Inhibition of rosette formation between antibody-coated SpA beads and platelets was studied in the same way, except that the blocking reagent was incubated first with the SpA beads and nonsensitized platelets were then added.
Results
Binding of antibody-coated platelets to SpA beads. Platelets coated with quinineor quinidine-induced antibodies in the presence of sensitizing drug (300 gM) readily formed rosettes about the SpA beads ( Fig. 1 A) . Pharmacologic concentrations of drug (10-30 gM) also induced rosette formation in this system (not shown). Elimination of drug from final incubation with SpA beads had little or no effect on rosette formation.
PlAI-positive platelets coated with an anti-PlA' antibody formed rosettes with SpA beads indistinguishable from those seen with ddAb-coated platelets. Frequently, platelets appeared to bind to each other as well as to the beads, forming layers around the beads. It is unlikely that this apparent platelet-platelet binding was due to aggregation, since it occurred in the presence of 8 mM EDTA and, in some experiments, 20 ng/ ml PGEI, which is a potent inhibitor of aggregation (10) .
Platelets incubated with ddAb in the absence of drug failed to form rosettes (Fig. 1 C) . No rosettes formed between SpA beads and PlA'-negative platelets pretreated with anti-PlAl antibody. Negative reactions always appeared as shown in Binding of platelets to antibody-coated SpA beads. To investigate the molecular orientation of ddAb bound simultaneously to platelets and SpA beads, partially purified ddAb was immobilized by its Fc region on SpA beads and then incubated with platelets in the presence and absence of the sensitizing drug (300 gM). Rosettes formed readily between platelets and ddAb-coated SpA beads, but only when drug was included in the incubation mixture. In contrast to the multi-layered binding of antibody-coated platelets to SpA beads ( Fig.  I A) , unsensitized platelets generally became bound to antibodycoated SpA beads in a monolayer (Fig. 1 B) . Rosettes essentially identical to those shown in Fig. 1 B formed when PlAI-positive platelets were incubated with SpA beads coated with the anti-PI"A antibody. Platelets failed to form rosettes with SpA beads coated with normal human IgG incubated in the presence or absence of drug, and PlAW-negative platelets did not form rosettes with SpA beads coated with anti-PI" antibody ( Fig. 1   C) . These findings suggested that rosette formation was associated with the binding of antibody by its Fc end to SpA beads and its Fab end to platelets.
Inhibition ofrosetteformation with anti-Fc and anti-F(alf2.
To further test this hypothesis, attempts were made to inhibit rosette formation with affinity purified F(ab')2 fragments directed against the Fc and F(ab')2 regions of human IgG. When ddAb absorbed to SpA beads were incubated with one or the other of the two blocking antibodies, anti-F(ab')2 at 5-50 jig/ ml prevented rosette formation by subsequently added platelets and drug while anti-Fc failed to inhibit even at 500 jg/ml (Table I) . The same was true of rosette formation between platelets and SpA beads coated with anti-PI"A. In the converse experiment, when platelets were first coated with the anti-PlAI antibody or ddAb and then incubated with blocking antibody at 50 gg/ml, anti-Fc inhibited rosette formation with subsequently added SpA beads while the same quantity of anti-F(ab'h was ineffective (Tablp, I). However, rosette formation was blocked with 10 times this amount of anti-F(ab')2.
Thus, anti-Fc effectively blocks rosette formation by platelets coated with ddAb or anti-PlAI antibody but fails to do so when nonsensitized platelets are incubated with antibody-coated SpA beads. Conversely, small quantities of anti-F(ab')2 effectively block rosette formation when nonsensitized platelets are incubated with antibody-coated SpA beads, but not when the antibodies are first bound to platelets, except at very high concentration.
Discussion
Our findings suggest that ddAb bind to platelets by their Fab combining sites in the presence of drug, leaving the Fc portion of the antibody molecules free for attachment to SpA beads. This conclusion is supported by the following observations: (a) in all experiments, an anti-PIA antibody behaved identically to the four ddAb studied; (b) platelet-platelet binding was seen when rosettes were formed with antibody-coated platelets and SpA beads, presumably because the divalent antibody molecules were capable of attaching simultaneously to more than one platelet; and (c) rosette formation was blocked preferentially by incubating ddAb-coated platelets with antibody directed against the Fc portion of the IgG molecule or by incubating ddAb-coated SpA beads with antibody directed against the F(ab')2 region. We are uncertain why high concentrations (500 ttg/ml) of anti-F(ab')2 inhibited rosette formation between antibody-coated platelets and SpA beads (Table I) . Extremely high levels of anti-F(ab')2 might competitively displace bound ddAb and anti-PlAI antibody from the platelet surface. This possibility is currently being investigated.
McVeigh and Chesterman (1 1) found that platelets coated with a single quinine-induced antibody in the presence of drug were preferentially retained on a column of SpA beads, but they did not comment on the possible relationship of this finding to the mechanism of drug-antibody-platelet interaction.
Chong et al. (12) recently described immunoprecipitation of a quinidine-induced antibody complexed to glycoproteins lb and IX by intact S. aureus cells in the presence of drug. These reports, together with our findings, all indicate that the ddAb molecule is capable of reacting simultaneously with protein A (either Sepharose bound or bacterial cell wall bound) and a platelet binding site in the presence of drug. While it is conceivable that one portion of the Fc region of ddAb reacts with platelets and a different Fc domain reacts with protein A, the most plausible explanation for these observations is that ddAb bind to a site or sites on the platelet membrane via the Fab portion of the antibody molecule, thus leaving the Fc region available for protein A binding.
Recent studies by van Leeuwen et al. (4) and Lerner et al. (5), using two different quinidine-induced antibodies, failed to demonstrate binding of F(ab')2 fragments of these antibodies to platelets in the presence of drug, which led both groups of investigators to conclude that ddAb bind to platelets via the Fc portion of the antibody molecule. However, neither report showed that the F(ab')2 fiagments retained their ability to interact with drug. In fact, we are unaware of any report showing that Fab or F(ab')2 fragments of ddAb are capable of binding to drug or platelets. It seems possible that the Fc portion of the ddAb molecule somehow stabilizes the F(ab')2 portion and that digestion with an enzyme like pepsin destroys the binding activity of the Fab combining sites. Alternatively, the methods used by van Ackroyd (13) proposed a mechanism for the drug-ddAbplatelet reaction in which drug, acting as a hapten, modified a platelet constituent to produce a hapten-carrier complex which induces antibody formation. Under this hypothesis, subsequent exposure of a sensitized individual to drug would lead to drugcoated platelets that are then bound by ddAb. An alternate model was proposed independently by Miescher and Miescher (14) and Shulman (15) in which some macromolecule unrelated to platelets, such as a plasma protein, is modified by drug to produce the hapten-carrier complex that induces antibody production. When a sensitized individual is rechallenged with drug, drug and antibody combine first to form soluble complexes which then bind to platelets in a second step ("innocent bystander" reaction) (16, 17) . Shulman (2) provided experimental support for the latter hypothesis by showing that quinidine binds only weakly to platelets and would, therefore, be unlikely to form complexes capable of inducing antibody, and that high concentrations of drug do not displace plateletbound ddAb, as would be expected in a conventional hapten inhibition reaction. We confirmed and extended these observations by showing that even platelets coated with a million molecules of drug do not express ddAb binding sites unless excess soluble drug is present (3) . Although these findings supported the "innocent bystander" mechanism for drug-ddAb-platelet interaction in drug-induced immunologic thrombocytopenia, they did not rule out the possibility that drug reacts first with platelets to induce a reversible confirmational change in the membrane, which would result in expression of a "neoantigen" to which ddAb then binds (3) .
Our studies show that platelets coated with ddAb in the presence of drug at concentrations that can be achieved therapeutically form rosettes with SpA beads. Since our data support the possibility that ddAb bind to platelets via their Fab combining sites, it is reasonable to conclude that, at the onset of thrombocytopenia, circulating platelets are directly recognized as an antigen by ddAb in the presence of drug.
These observations seem most consistent with the following model for drug-ddAb-platelet binding: platelets coated with drug express an unstable neoantigen which is stabilized upon interaction with the Fab domains of ddAb (3) . We and others previously showed that the expression of this putative platelet neoantigen is dependent on the continued presence of drug in the suspension medium. That is, platelets pretreated with drug and then washed do not express binding sites for ddAb, and bound ddAb can readily be removed from platelets by washing in the absence of drug (3). However, ddAb-coated platelets retain significantly more drug after multiple washes than uncoated platelets (3) . The molecular nature of the putative neoantigen(s) and the mechanism(s) by which it is expressed are subjects of current investigation.
